These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 16105484)

  • 1. Pleiotropic effects of fibrates.
    Chinetti-Gbaguidi G; Fruchart JC; Staels B
    Curr Atheroscler Rep; 2005 Sep; 7(5):396-401. PubMed ID: 16105484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fibrates consistently lower risk of cardiovascular events across high-risk groups.
    Aalbers J
    Cardiovasc J Afr; 2010; 21(3):174. PubMed ID: 20532463
    [No Abstract]   [Full Text] [Related]  

  • 3. [Fibrates in the light of large clinical trials].
    Krysiak R; Rudzki H; Handzlik-Orlik G; Gdula-Dymek A; Okopień B
    Pol Merkur Lekarski; 2015 Apr; 38(226):222-7. PubMed ID: 25938391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cross-talk between statins and PPARalpha in cardiovascular diseases: clinical evidence and basic mechanisms.
    Paumelle R; Staels B
    Trends Cardiovasc Med; 2008 Apr; 18(3):73-8. PubMed ID: 18436144
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Nuclear receptors PPARalpha].
    Soska V
    Vnitr Lek; 2006 Jun; 52(6):628-31. PubMed ID: 16871768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fibrates in CVD: a step towards personalised medicine.
    Staels B
    Lancet; 2010 May; 375(9729):1847-8. PubMed ID: 20510999
    [No Abstract]   [Full Text] [Related]  

  • 7. Fibrate therapy: an update.
    Remick J; Weintraub H; Setton R; Offenbacher J; Fisher E; Schwartzbard A
    Cardiol Rev; 2008; 16(3):129-41. PubMed ID: 18414184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fibrates: where are we now?
    Seth Loomba R; Arora R
    Ther Adv Cardiovasc Dis; 2009 Feb; 3(1):91-6. PubMed ID: 19144670
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibrates, dyslipoproteinaemia and cardiovascular disease.
    Watts GF; Dimmitt SB
    Curr Opin Lipidol; 1999 Dec; 10(6):561-74. PubMed ID: 10680050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.
    Fruchart JC; Duriez P
    Drugs Today (Barc); 2006 Jan; 42(1):39-64. PubMed ID: 16511610
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of fibrates on cardiovascular outcomes.
    Delanaye P; Scheen AJ
    Lancet; 2010 Sep; 376(9746):1051; author reply 1051-2. PubMed ID: 20870090
    [No Abstract]   [Full Text] [Related]  

  • 12. Fibrates and microvascular complications in diabetes--insight from the FIELD study.
    Ansquer JC; Foucher C; Aubonnet P; Le Malicot K
    Curr Pharm Des; 2009; 15(5):537-52. PubMed ID: 19199980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Factors modulating fibrates response: therapeutic implications and alternative strategies.
    Panadero MI; González MC; Herrera E; Bocos C
    Endocr Metab Immune Disord Drug Targets; 2009 Sep; 9(3):219-36. PubMed ID: 19594420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fibrates, glitazones, and peroxisome proliferator-activated receptors.
    Lalloyer F; Staels B
    Arterioscler Thromb Vasc Biol; 2010 May; 30(5):894-9. PubMed ID: 20393155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Belgian expert opinion: how to reduce the residual risk in atherogenic dyslipidaemic patients: place of fibrates.
    Ducobu J; Scheen A; Van Gaal L; Velkeniers B; Hermans M
    Acta Cardiol; 2008 Apr; 63(2):235-48. PubMed ID: 18468206
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Fibrates and markers of inflammation].
    Broncel M
    Pol Merkur Lekarski; 2007 Jan; 22(127):58-61. PubMed ID: 17477093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of fibrate treatment in dyslipidemia: an overview.
    Katsiki N; Nikolic D; Montalto G; Banach M; Mikhailidis DP; Rizzo M
    Curr Pharm Des; 2013; 19(17):3124-31. PubMed ID: 23317397
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of fibrates on cardiovascular outcomes.
    Braillon A
    Lancet; 2010 Sep; 376(9746):1051; author reply 1051-2. PubMed ID: 20870092
    [No Abstract]   [Full Text] [Related]  

  • 19. The role of fibrates in the prevention of cardiovascular disease--a pooled meta-analysis of long-term randomized placebo-controlled clinical trials.
    Saha SA; Kizhakepunnur LG; Bahekar A; Arora RR
    Am Heart J; 2007 Nov; 154(5):943-53. PubMed ID: 17967602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A clinical puzzle: fibrates and homocysteine elevation: editorial to: "fibrates may cause an abnormal urinary betaine loss which is associated with elevations in plasma homocysteine" by M. Lever et al.
    Davidson MH
    Cardiovasc Drugs Ther; 2009 Oct; 23(5):341-2. PubMed ID: 19844785
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.